Cure My Disease

Don't miss your cure!

 Log in / Sign up

Algae extract could shield menopausal brains from mental decline

NCT ID NCT07600567

Symptom relief Sponsor: Poznan University of Life Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily lutein supplement made from microalgae can slow cognitive decline in postmenopausal women with obesity. 300 women aged 48-60 will take either 6 mg, 14 mg, or a placebo for 180 days. Researchers will measure changes in memory, attention, and inflammation markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lutein (from microalgae)
What this could lead to
If it works, this could point toward a simple dietary supplement to help protect thinking skills and reduce inflammation in postmenopausal women.
What could go wrong
This is an early-stage trial with no phase designation, so results are uncertain. The study only includes a specific group (postmenopausal women with obesity), so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

48 to 60 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females * Age 48-60 years * Postmenopausal status (natural menopause, up to 5 years after menopause) * waist circumference ≥ 88 cm Exclusion Criteria: * Diagnosis of dementia or cognitive impairment * Use of hormone replacement therapy within the last 6 months * Advanced age-related macular degeneration * History of major untreated neurological or psychiatric disorders (including depression, Parkinson's disease, Alzheimer's disease, psychiatric disorders, stroke within the last 3 months) * Presence of chronic diseases, including: diabetes mellitus (type 1 or 2), lipid disorders, cardiovascular diseases, thyroid diseases, anemia, liver diseases, gastrointestinal disorders, or cancer within the last 5 years * Use of anti-inflammatory medications or medications targeting lipid or carbohydrate metabolism within the last 3 months * Alcohol consumption \> 100 g per week * Use of lutein-containing supplements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bisphenol A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Cognitive Dysfunction Dysbiosis Inflammation inflammatory disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bisphenol A Cardio vascular disease Cognitive decline Gut dysbiosis Inflamation Menopausal syndrome Menopause Obesity & overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Food Science and Nutrition, Poznan University of Life Sciences

    Poznan, 60-637, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.